Abeona Therapeutics Inc.
BiotechAbeona Therapeutics Inc. is a biotechnology company focused on Immunology, Dermatology. Key products include zevaskyn.
Abeona Therapeutics Inc.'s Key Drugs
Abeona Therapeutics Inc.'s core commercial portfolio centers on zevaskyn, spanning Immunology and Dermatology — its most strategically important drugs approved in the last 15 years.
Abeona Therapeutics Inc.'s Recent FDA Approvals
Abeona Therapeutics Inc. secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
Abeona Therapeutics Inc.'s Therapeutic Areas
Abeona Therapeutics Inc.'s approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Dermatology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Abeona Therapeutics Inc.'s Top Competitors
Abeona Therapeutics Inc.'s closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Abeona Therapeutics Inc. Pipeline Snapshot
Abeona Therapeutics Inc. has 15 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 8 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • zevaskyn leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-04-27
- Latest
- 2025-04-27
- Applications
- 1